Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →

Clinical Laboratory Diagnostic Testing Services – Renasight Kidney Gene Test

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract facilitates the provision of proprietary genetic testing services through the Renasight Kidney Gene test to support the diagnosis of kidney disease among Veterans. This subcontract encompasses the full lifecycle of specimen handling, including collection, processing, genetic analysis, and the secure generation and delivery of clinical reports to authorized providers. The services are designed to enable accurate, personalized diagnostic insights for kidney-related conditions, leveraging advanced genomic technology specifically validated for this clinical application. All operations must comply with stringent data security and privacy standards to protect Veteran health information. The contract is issued under the 246-NETWORK Contracting Office 6 within the Department of Veterans Affairs and is classified under NAICS code 621511 for clinical laboratory services. It is solicited as a subcontract with a narrow response window closing on July 13, 2026, indicating an urgent need to establish or expand capacity in genomic diagnostics within the VA healthcare system. Performance is not limited to a specific geographic location, allowing the contractor to operate wherever logistical and regulatory requirements are met. There is no set-aside classification, meaning all eligible entities may compete, and the focus is on delivering reliable, timely, and clinically actionable genetic test results to improve Veteran outcomes.

General Info

Renasight Kidney Gene test provides genetic diagnostics for Veterans, with secure specimen handling and clinical reporting under VA oversight.

Agency

Department Of Veterans Affairs → 246-NETWORK Contracting Office 6 (36C246)View Agency

NAICS

621511 - Medical LaboratoriesView NAICS

Place of Performance

VA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Veterans Affairs → 246-NETWORK Contracting Office 6 (36C246)
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Veterans Affairs → 246-NETWORK Contracting Office 6 (36C246)
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Provision of proprietary genetic testing services using the Renasight Kidney Gene test for diagnosis of kidney disease in Veterans, including specimen processing, analysis, reporting, and secure delivery of results.

Similar Contracts

NAICS: 621511
New
Federal
Q301--T-SPOT.TB Assay TestingThe Department of Veterans Affairs, Network Contracting Office 16, intends to award a sole source, firm-fixed price purchase order to Quest Diagnostics for T SPOT.TB testing services, with the possibility of two optional extension years. The contract requires the performance of the T SPOT.TB assay, daily specimen pickup, secure transport, and full compliance with CLIA, CAP, and VA reporting standards. Quest Diagnostics is identified as the only responsible source capable of meeting all technical, regulatory, logistical, and stability requirements necessary to ensure timely and reliable testing without compromising VA screening operations. This decision is based on the unique combination of accreditation, validated assay performance, strict specimen stability windows, and daily courier logistics that no other provider can currently fulfill without introducing unacceptable risk. This notice serves as a formal announcement of intent to proceed without competition under FAR 6.302-1, but it invites interested parties to submit clear and convincing evidence demonstrating their ability to meet all requirements by July 26, 2026, at 7:00 a.m. CST. Responses must be submitted via email in Microsoft Word or PDF format to Contract Specialist William Shaver and must include documented proof of in-house assay capability, current CLIA and CAP accreditation, daily courier services, adherence to specimen stability timelines, and full compliance with VA reporting protocols. The Government will not acknowledge receipt or provide feedback on submissions, will not compensate for information provided, and retains full discretion to proceed with the sole source award regardless of any responses received. No telephone inquiries will be accepted, and this notice does not create any obligation on the part of the Government to award a contract.
256-NETWORK Contract Office 16 (36C256)

POSTED

about 23 hours ago

DEADLINE

in 16 days
View Details
NAICS: 621511
New
Federal
Q301--T-SPOT.TB Assay TestingThe Department of Veterans Affairs, Network Contracting Office 16, is pursuing a sole source procurement for T-SPOT.TB testing services under NAICS code 621511 and PSC code Q301, exclusively targeting Quest Diagnostics due to its unique and irreplaceable capability to meet all regulatory, logistical, and technical requirements. The requirement spans a base period from October 1, 2026, through September 30, 2027, with one optional one-year renewal extending through September 30, 2028, covering an estimated annual volume of 1,700 tests. Services include in-house performance of the T-SPOT.TB assay, daily Monday through Friday courier pickups from the G.V. (Sonny) Montgomery VAMC in Jackson, Mississippi, secure specimen transportation ensuring processing within the 32-hour manufacturer-specified stability window, and delivery of results within 72 hours of specimen receipt via fax to VA-specific channels with full integration into VISTA workflows and inclusion of VA identifiers (ICN or EDIPI). The contractor must maintain active CLIA and CAP accreditations covering immunologic and ELISPOT-based assays, provide certification documentation to the Jackson VAMC, and fully comply with all VA information security, privacy, and records management directives, including Title 38 U.S.C. 5705 and 7332, as well as VA Directive 0710 for personnel background investigations. All personnel must complete VA privacy training annually and sign the Contractor Rules of Behavior, with subcontractors bound by the same obligations through flow-down clauses. The government retains rights to conduct on-site inspections of IT resources and evaluate security controls, and performance will be monitored through a Quality Assurance Surveillance Plan with metrics covering service quality, turnaround time, and business relations, with final determinations resting with the Contracting Specialist. The notice, issued as a Sources Sought Notice under FAR 6.302-1, seeks evidence from other potential providers to confirm the sole source justification, with responses due by July 26, 2026, submitted electronically to William Shaver in Word or PDF format, including full technical, accreditation, security, and business size documentation such as UEI and CAGE codes. No compensation will be provided for submission of information, and the government is under no obligation to proceed with a contract based on responses received.
256-NETWORK Contract Office 16 (36C256)

POSTED

about 23 hours ago

DEADLINE

in 16 days
View Details
NAICS: 621511
New
Grant
Continuing Enhanced National Surveillance for Prion Diseases in the United StatesThe Centers for Disease Control and Prevention is seeking to award funding through a cooperative agreement to sustain and enhance national surveillance for human prion diseases, also known as transmissible spongiform encephalopathies, in the United States for fiscal year 2027. The primary objective is to maintain an active, standardized system for confirming suspected cases through advanced diagnostic methods that require specialized laboratory capabilities, as definitive diagnosis of these invariably fatal conditions can only be achieved via brain tissue analysis. Many healthcare facilities lack the expertise or the infrastructure to safely handle and process such specimens due to infection control concerns, making centralized diagnostic support essential. Since 1997, CDC has supported a designated center for this purpose, enabling consistent case confirmation, tracking of disease trends, and identification of disease subtypes, all critical for public health monitoring. This continuing effort relies on a highly collaborative model, with CDC epidemiologists working closely with the funded center’s staff to interpret data, guide surveillance priorities, and evaluate potential emerging threats. The program has played a pivotal role in ensuring the reliability of national data and in confirming that novel prion disease forms, such as those potentially linked to chronic wasting disease in animals, have not emerged in the U.S. population. The funding will support state-of-the-art diagnostic techniques, personnel, laboratory operations, and ongoing data sharing mechanisms to maintain robust, nationwide surveillance. The point of contact for inquiries is Lisa Angel at the CDC’s National Center for Emerging and Zoonotic Infectious Diseases, and the solicitation is listed as a forecast with an anticipated posting date in July 2026.
Centers For Disease Control - Ncezid

POSTED

1 day ago

DEADLINE

N/A
View Details